A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Clinical trial NCT07132983 · COMPLETED
Trial details
- NCT number
- NCT07132983
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-06
- Primary completion
- 2025-11-28
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.